Not logged in
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
SaveInitial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
Shapira-Frommer, R.; Sudo, K.; Harano, K.; Mileshkin, L.; Perets, R.; Song, M.; Cohen, J.; Huang, Y-F.; Ambrose, H.; Brier, T.; Dosani, A.; Fraenkel, P. G.; Kmieciak, A.; Mitchell, P.; Myers, C.; Wang, J.; Odegbami, R. I.; Sykes, A.; Turner, S.; Meric-Bernstam, F.
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save